PMID- 27991928
OWN - NLM
STAT- MEDLINE
DCOM- 20170907
LR  - 20211204
IS  - 1476-5594 (Electronic)
IS  - 0950-9232 (Print)
IS  - 0950-9232 (Linking)
VI  - 36
IP  - 19
DP  - 2017 May 11
TI  - Stem cell-like transcriptional reprogramming mediates metastatic resistance to 
      mTOR inhibition.
PG  - 2737-2749
LID - 10.1038/onc.2016.427 [doi]
AB  - Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to 
      treat advanced metastatic breast cancer. However, whether an aggressive phenotype 
      is sustained through adaptation or resistance to mTOR inhibition remains unknown. 
      Here, complementary studies in human tumors, cancer models and cell lines reveal 
      transcriptional reprogramming that supports metastasis in response to mTOR 
      inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally 
      cooperates with and positively regulates SOX9, and promotes the transcriptional 
      upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung 
      metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is 
      associated with stem cell-like and metastasis signatures, and their depletion 
      impairs the metastatic potential of breast cancer cells. These results establish 
      the mechanistic link between resistance to mTOR inhibition and cancer metastatic 
      potential, thus enhancing our understanding of mTOR targeting failure.
FAU - Mateo, F
AU  - Mateo F
AD  - Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic 
      Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute 
      for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Arenas, E J
AU  - Arenas EJ
AD  - Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The 
      Barcelona Institute of Science and Technology, Barcelona, Spain.
FAU - Aguilar, H
AU  - Aguilar H
AD  - Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic 
      Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute 
      for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Serra-Musach, J
AU  - Serra-Musach J
AD  - Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic 
      Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute 
      for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - de Garibay, G Ruiz
AU  - de Garibay GR
AD  - Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic 
      Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute 
      for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Boni, J
AU  - Boni J
AD  - Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic 
      Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute 
      for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Maicas, M
AU  - Maicas M
AD  - Centre for Applied Medical Research (CIMA) and Department of Biochemistry and 
      Genetics, University of Navarra, Pamplona, Spain.
FAU - Du, S
AU  - Du S
AD  - Department of Radiation Oncology, New York University School of Medicine, New 
      York, NY, USA.
FAU - Iorio, F
AU  - Iorio F
AD  - European Molecular Biology Laboratory-European Bioinformatics Institute 
      (EMBL-EBI), Wellcome Trust Genome Campus, Cambridge, UK.
AD  - Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
FAU - Herranz-Ors, C
AU  - Herranz-Ors C
AD  - Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic 
      Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute 
      for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Islam, A
AU  - Islam A
AD  - Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, 
      Bangladesh.
FAU - Prado, X
AU  - Prado X
AD  - Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic 
      Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute 
      for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Llorente, A
AU  - Llorente A
AD  - Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic 
      Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute 
      for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Petit, A
AU  - Petit A
AD  - Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet 
      del Llobregat, Barcelona, Spain.
FAU - Vidal, A
AU  - Vidal A
AD  - Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet 
      del Llobregat, Barcelona, Spain.
FAU - Catala, I
AU  - Catala I
AD  - Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet 
      del Llobregat, Barcelona, Spain.
FAU - Soler, T
AU  - Soler T
AD  - Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet 
      del Llobregat, Barcelona, Spain.
FAU - Venturas, G
AU  - Venturas G
AD  - Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet 
      del Llobregat, Barcelona, Spain.
FAU - Rojo-Sebastian, A
AU  - Rojo-Sebastian A
AD  - Department of Pathology, MD Anderson Cancer Center, Madrid, Spain.
FAU - Serra, H
AU  - Serra H
AD  - Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, 
      Barcelona, Spain.
FAU - Cuadras, D
AU  - Cuadras D
AD  - Statistics Unit, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Blanco, I
AU  - Blanco I
AD  - Hereditary Cancer Programme, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, 
      Spain.
FAU - Lozano, J
AU  - Lozano J
AD  - Department of Molecular Biology and Biochemistry, Malaga University, and 
      Molecular Oncology Laboratory, Mediterranean Institute for the Advance of 
      Biotechnology and Health Research (IBIMA), University Hospital Virgen de la 
      Victoria, Malaga, Spain.
FAU - Canals, F
AU  - Canals F
AD  - ProteoRed-Instituto de Salud Carlos III, Proteomic Laboratory, Vall d'Hebron 
      Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, 
      Spain.
FAU - Sieuwerts, A M
AU  - Sieuwerts AM
AD  - Department of Medical Oncology, Erasmus University Medical Center, Daniel den 
      Hoed Cancer Center, Cancer Genomics Centre, Rotterdam, The Netherlands.
FAU - de Weerd, V
AU  - de Weerd V
AD  - Department of Medical Oncology, Erasmus University Medical Center, Daniel den 
      Hoed Cancer Center, Cancer Genomics Centre, Rotterdam, The Netherlands.
FAU - Look, M P
AU  - Look MP
AD  - Department of Medical Oncology, Erasmus University Medical Center, Daniel den 
      Hoed Cancer Center, Cancer Genomics Centre, Rotterdam, The Netherlands.
FAU - Puertas, S
AU  - Puertas S
AD  - Chemoresistance and Predictive Factors Laboratory, ProCURE, ICO, IDIBELL, 
      L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Garcia, N
AU  - Garcia N
AD  - Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic 
      Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute 
      for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Perkins, A S
AU  - Perkins AS
AD  - University of Rochester Medical Center, School of Medicine and Dentistry, 
      Rochester, NY, USA.
FAU - Bonifaci, N
AU  - Bonifaci N
AD  - Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic 
      Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute 
      for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Skowron, M
AU  - Skowron M
AD  - Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic 
      Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute 
      for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Gomez-Baldo, L
AU  - Gomez-Baldo L
AD  - Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic 
      Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute 
      for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Hernandez, V
AU  - Hernandez V
AD  - Biological Clues of the Invasive and Metastatic Phenotype Laboratory, IDIBELL, 
      L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Martinez-Aranda, A
AU  - Martinez-Aranda A
AD  - Biological Clues of the Invasive and Metastatic Phenotype Laboratory, IDIBELL, 
      L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Martinez-Iniesta, M
AU  - Martinez-Iniesta M
AD  - Chemoresistance and Predictive Factors Laboratory, ProCURE, ICO, IDIBELL, 
      L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Serrat, X
AU  - Serrat X
AD  - Cancer and Human Molecular Genetics, IDIBELL, Hospitalet de Llobregat, Barcelona, 
      Spain.
FAU - Ceron, J
AU  - Ceron J
AD  - Cancer and Human Molecular Genetics, IDIBELL, Hospitalet de Llobregat, Barcelona, 
      Spain.
FAU - Brunet, J
AU  - Brunet J
AD  - Hereditary Cancer Programme, ICO, Girona Biomedical Research Institute (IDIBGI), 
      Girona, Spain.
FAU - Barretina, M P
AU  - Barretina MP
AD  - Department of Medical Oncology, ICO, IDIBGI, Girona, Spain.
FAU - Gil, M
AU  - Gil M
AD  - Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, 
      Barcelona, Spain.
FAU - Falo, C
AU  - Falo C
AD  - Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, 
      Barcelona, Spain.
FAU - Fernandez, A
AU  - Fernandez A
AD  - Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, 
      Barcelona, Spain.
FAU - Morilla, I
AU  - Morilla I
AD  - Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, 
      Barcelona, Spain.
FAU - Pernas, S
AU  - Pernas S
AD  - Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, 
      Barcelona, Spain.
FAU - Pla, M J
AU  - Pla MJ
AD  - Department of Gynecology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet 
      del Llobregat, Barcelona, Spain.
FAU - Andreu, X
AU  - Andreu X
AD  - Department of Pathology, Parc Tauli Hospital Consortium, Sabadell, Barcelona, 
      Spain.
FAU - Segui, M A
AU  - Segui MA
AD  - Medical Oncology Service, Parc Tauli Hospital Consortium, Sabadell, Barcelona, 
      Spain.
FAU - Ballester, R
AU  - Ballester R
AD  - Department of Radiation Oncology, University Hospital Germans Trias i Pujol, ICO, 
      Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
FAU - Castella, E
AU  - Castella E
AD  - Department of Pathology, University Hospital Germans Trias i Pujol, ICO, IGTP, 
      Badalona, Barcelona, Spain.
FAU - Nellist, M
AU  - Nellist M
AD  - Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, The 
      Netherlands.
FAU - Morales, S
AU  - Morales S
AD  - Hospital Arnau de Vilanova, University of Lleida, Biomedical Research Institute 
      of Lleida (IRB Lleida), Lleida, Spain.
FAU - Valls, J
AU  - Valls J
AD  - Hospital Arnau de Vilanova, University of Lleida, Biomedical Research Institute 
      of Lleida (IRB Lleida), Lleida, Spain.
FAU - Velasco, A
AU  - Velasco A
AD  - Hospital Arnau de Vilanova, University of Lleida, Biomedical Research Institute 
      of Lleida (IRB Lleida), Lleida, Spain.
FAU - Matias-Guiu, X
AU  - Matias-Guiu X
AD  - Hospital Arnau de Vilanova, University of Lleida, Biomedical Research Institute 
      of Lleida (IRB Lleida), Lleida, Spain.
FAU - Figueras, A
AU  - Figueras A
AD  - Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, 
      Barcelona, Spain.
FAU - Sanchez-Mut, J V
AU  - Sanchez-Mut JV
AD  - Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del 
      Llobregat, Barcelona, Spain.
FAU - Sanchez-Cespedes, M
AU  - Sanchez-Cespedes M
AD  - Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del 
      Llobregat, Barcelona, Spain.
FAU - Cordero, A
AU  - Cordero A
AD  - Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del 
      Llobregat, Barcelona, Spain.
FAU - Gomez-Miragaya, J
AU  - Gomez-Miragaya J
AD  - Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del 
      Llobregat, Barcelona, Spain.
FAU - Palomero, L
AU  - Palomero L
AD  - Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic 
      Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute 
      for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Gomez, A
AU  - Gomez A
AD  - Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del 
      Llobregat, Barcelona, Spain.
FAU - Gajewski, T F
AU  - Gajewski TF
AD  - Departments of Pathology and Medicine, University of Chicago, Chicago, IL, USA.
FAU - Cohen, E E W
AU  - Cohen EEW
AD  - Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
FAU - Jesiotr, M
AU  - Jesiotr M
AD  - Department of Pathology, Military Institute of Medicine, Warsaw, Poland.
FAU - Bodnar, L
AU  - Bodnar L
AD  - Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
FAU - Quintela-Fandino, M
AU  - Quintela-Fandino M
AD  - Breast Cancer Clinical Research Unit, Spanish National Cancer Research Center 
      (CNIO), Madrid, Spain.
FAU - Lopez-Bigas, N
AU  - Lopez-Bigas N
AD  - Department of Experimental and Health Sciences, Barcelona Biomedical Research 
      Park, Pompeu Fabra University (UPF), Barcelona, Spain.
AD  - Institucio Catalana de Recerca i Estudis Avancats (ICREA), Barcelona, Spain.
FAU - Valdes-Mas, R
AU  - Valdes-Mas R
AD  - Department of Biochemistry and Molecular Biology, University Institute of 
      Oncology of Asturias, University of Oviedo, Oviedo, Spain.
FAU - Puente, X S
AU  - Puente XS
AD  - Department of Biochemistry and Molecular Biology, University Institute of 
      Oncology of Asturias, University of Oviedo, Oviedo, Spain.
FAU - Vinals, F
AU  - Vinals F
AD  - Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, 
      Barcelona, Spain.
FAU - Casanovas, O
AU  - Casanovas O
AD  - Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, 
      Barcelona, Spain.
FAU - Graupera, M
AU  - Graupera M
AD  - Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, 
      Barcelona, Spain.
FAU - Hernandez-Losa, J
AU  - Hernandez-Losa J
AD  - Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain.
FAU - Ramon Y Cajal, S
AU  - Ramon Y Cajal S
AD  - Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain.
FAU - Garcia-Alonso, L
AU  - Garcia-Alonso L
AD  - European Molecular Biology Laboratory-European Bioinformatics Institute 
      (EMBL-EBI), Wellcome Trust Genome Campus, Cambridge, UK.
FAU - Saez-Rodriguez, J
AU  - Saez-Rodriguez J
AD  - European Molecular Biology Laboratory-European Bioinformatics Institute 
      (EMBL-EBI), Wellcome Trust Genome Campus, Cambridge, UK.
FAU - Esteller, M
AU  - Esteller M
AD  - Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del 
      Llobregat, Barcelona, Spain.
AD  - Institucio Catalana de Recerca i Estudis Avancats (ICREA), Barcelona, Spain.
AD  - Department of Physiological Sciences II, School of Medicine, University of 
      Barcelona, Barcelona, Spain.
FAU - Sierra, A
AU  - Sierra A
AD  - Molecular and Translational Oncology Laboratory, Biomedical Research Center 
      CELLEX-CRBC, Biomedical Research Institute 'August Pi i Sunyer' (IDIBAPS), and 
      Systems Biology Department, Faculty of Science and Technology, University of Vic, 
      Central University of Catalonia, Barcelona, Spain.
FAU - Martin-Martin, N
AU  - Martin-Martin N
AD  - Center for Cooperative Research in Biosciences (CIC bioGUNE), Derio, Spain.
FAU - Matheu, A
AU  - Matheu A
AD  - Neuro-Oncology Section, Oncology Department, Biodonostia Research Institute, San 
      Sebastian, Spain.
AD  - Ikerbasque, Basque Foundation for Science, Bilbao, Spain.
FAU - Carracedo, A
AU  - Carracedo A
AD  - Center for Cooperative Research in Biosciences (CIC bioGUNE), Derio, Spain.
AD  - Ikerbasque, Basque Foundation for Science, Bilbao, Spain.
AD  - Department of Biochemistry and Molecular Biology, University of the Basque 
      Country (UPV/EHU), Bilbao, Spain.
FAU - Gonzalez-Suarez, E
AU  - Gonzalez-Suarez E
AD  - Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del 
      Llobregat, Barcelona, Spain.
FAU - Nanjundan, M
AU  - Nanjundan M
AD  - Department of Cell Biology, Microbiology, and Molecular Biology, University of 
      South Florida, Tampa, FL, USA.
FAU - Cortes, J
AU  - Cortes J
AD  - Department of Medical Oncology, VHIO, Vall d'Hebron University Hospital, 
      Barcelona, Spain.
FAU - Lazaro, C
AU  - Lazaro C
AD  - Hereditary Cancer Programme, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, 
      Spain.
FAU - Odero, M D
AU  - Odero MD
AD  - Centre for Applied Medical Research (CIMA) and Department of Biochemistry and 
      Genetics, University of Navarra, Pamplona, Spain.
FAU - Martens, J W M
AU  - Martens JWM
AD  - Department of Medical Oncology, Erasmus University Medical Center, Daniel den 
      Hoed Cancer Center, Cancer Genomics Centre, Rotterdam, The Netherlands.
FAU - Moreno-Bueno, G
AU  - Moreno-Bueno G
AD  - Department of Biochemistry, Autonomous University of Madrid (UAM), Biomedical 
      Research Institute 'Alberto Sols' (Spanish National Research Council (CSIC)-UAM), 
      Translational Research Laboratory, Hospital La Paz Institute for Health Research 
      (IdiPAZ), and MD Anderson International Foundation, Madrid, Spain.
FAU - Barcellos-Hoff, M H
AU  - Barcellos-Hoff MH
AD  - Department of Radiation Oncology, New York University School of Medicine, New 
      York, NY, USA.
FAU - Villanueva, A
AU  - Villanueva A
AD  - Chemoresistance and Predictive Factors Laboratory, ProCURE, ICO, IDIBELL, 
      L'Hospitalet del Llobregat, Barcelona, Spain.
FAU - Gomis, R R
AU  - Gomis RR
AD  - Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The 
      Barcelona Institute of Science and Technology, Barcelona, Spain.
AD  - Institucio Catalana de Recerca i Estudis Avancats (ICREA), Barcelona, Spain.
FAU - Pujana, M A
AU  - Pujana MA
AD  - Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic 
      Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute 
      for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
LA  - eng
PT  - Journal Article
DEP - 20161219
PL  - England
TA  - Oncogene
JT  - Oncogene
JID - 8711562
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Carrier Proteins)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (FSCN1 protein, human)
RN  - 0 (MDS1 and EVI1 Complex Locus Protein)
RN  - 0 (MECOM protein, human)
RN  - 0 (Microfilament Proteins)
RN  - 0 (Osteonectin)
RN  - 0 (RPTOR protein, human)
RN  - 0 (Regulatory-Associated Protein of mTOR)
RN  - 0 (SOX9 Transcription Factor)
RN  - 0 (SOX9 protein, human)
RN  - 0 (SPARC protein, human)
RN  - 0 (Transcription Factors)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/genetics
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/*genetics/pathology
MH  - Carrier Proteins/genetics
MH  - Cell Proliferation/genetics
MH  - DNA-Binding Proteins/*genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lung Neoplasms/*genetics/pathology/secondary
MH  - MCF-7 Cells
MH  - MDS1 and EVI1 Complex Locus Protein
MH  - Microfilament Proteins/genetics
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Osteonectin/genetics
MH  - Proto-Oncogenes/*genetics
MH  - Regulatory-Associated Protein of mTOR
MH  - SOX9 Transcription Factor/*genetics
MH  - Signal Transduction/genetics
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/*genetics
MH  - Transcription Factors/*genetics
MH  - Xenograft Model Antitumor Assays
PMC - PMC5442428
COIS- The authors declare no conflict of interest.
EDAT- 2016/12/20 06:00
MHDA- 2017/09/08 06:00
PMCR- 2017/05/24
CRDT- 2016/12/20 06:00
PHST- 2016/03/10 00:00 [received]
PHST- 2016/08/31 00:00 [revised]
PHST- 2016/10/10 00:00 [accepted]
PHST- 2016/12/20 06:00 [pubmed]
PHST- 2017/09/08 06:00 [medline]
PHST- 2016/12/20 06:00 [entrez]
PHST- 2017/05/24 00:00 [pmc-release]
AID - onc2016427 [pii]
AID - 10.1038/onc.2016.427 [doi]
PST - ppublish
SO  - Oncogene. 2017 May 11;36(19):2737-2749. doi: 10.1038/onc.2016.427. Epub 2016 Dec 
      19.